Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-38840396

ABSTRACT

Caffeic acid, a phenolic compound of the hydroxycinnamic acid family, is abundant in various plant-based foods, such as fruits, vegetables, and coffee, alongside other biologically active compounds. Recognizing its potential to address various health issues and its widespread presence in commonly consumed foods underscores the importance of comprehending and harnessing the benefits of caffeic acid for human nutrition and well-being. This versatile substance, characterized by acrylic and phenolic functional groups, plays a pivotal role in the food and pharmaceutical industries. Furthermore, a detailed exploration of its pharmacokinetic properties, absorption, distribution, metabolism, and excretion enhances our understanding of how the human body processes it. Functioning as a precursor for essential compounds, caffeic acid contributes to formulations with notable anti-inflammatory, antiviral, anti-cancer, anti-diabetic, antibacterial, neuroprotective, and hepatoprotective qualities. Its current applications in treating Parkinson's and Alzheimer's disease underscore its therapeutic significance. This comprehensive analysis sheds light on caffeic acid's importance, showcasing its diverse applications across various domains and paving the way for further research and development to fully unlock its therapeutic potential. In conclusion, caffeic acid emerges as a bioactive substance with a broad spectrum of pharmacological properties, suggesting its potential utility in diverse therapeutic contexts. The comprehensive information provided in this article serves as a foundation for further research and learning regarding the various ways that caffeic acid supports human health.

2.
J Biochem Mol Toxicol ; 38(6): e23739, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38769721

ABSTRACT

Myricetin can be found in the traditional Chinese medicinal plant, Myrica rubra. Myricetin is a flavonoid that is present in many vegetables, fruits, and plants and is considered to have strong antioxidant properties as well as a wide range of therapeutic applications. Growing interest has been piqued by its classification as a polyphenolic molecule because of its potential therapeutic benefits in both the prevention and management of numerous medical conditions. To clarify myricetin's traditional medical uses, modern research has investigated various pharmacological effects such as antioxidant, anticancer, anti-inflammation, antiviral, antidiabetic, immunomodulation, and antineurodegenerative effects. Myricetin shows promise as a nutritional flavonol that could be beneficial in the prevention and mitigation of prevalent health conditions like diabetes, cognitive decline, and various types of cancer in humans. The findings included in this study indicate that myricetin has a great deal of promise for application in the formulation of medicinal products and nutritional supplements since it affects several enzyme activities and alters inflammatory markers. However, comprehensive preclinical studies and research studies are necessary to lay the groundwork for assessing myricetin's possible effectiveness in treating these long-term ailments. This review summarizes both in vivo and in vitro studies investigating myricetin's possible interactions through the nuclear factor-E2-related factor 2 (Nrf2) as well as PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B) signaling pathways in an attempt to clarify the compound's possible clinical applicability across a range of disorders.


Subject(s)
Flavonoids , NF-E2-Related Factor 2 , Phosphatidylinositol 3-Kinases , Proto-Oncogene Proteins c-akt , Signal Transduction , NF-E2-Related Factor 2/metabolism , Flavonoids/pharmacology , Flavonoids/chemistry , Humans , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects , Phosphatidylinositol 3-Kinases/metabolism , Animals
3.
Chem Biol Drug Des ; 103(1): e14426, 2024 01.
Article in English | MEDLINE | ID: mdl-38230775

ABSTRACT

Neurodegenerative disorders, which affect millions worldwide, are marked by a steady decline of neurons that are selectively susceptible. Due to the complex pathological processes underlying neurodegeneration, at present, there is no viable therapy available for neurodegenerative disorders. Consequently, the establishment of a novel therapeutic approach for such conditions is a clinical void that remains. The potential significance of various peptides as neuroprotective interventions for neurodegenerative disorders is gaining increasing attention. In the past few years, there has been growing scientific interest in glucagon-like peptide-1 receptor agonists due to their claimed neuroprotective effects. Exendin-4 is a glucagon-like peptide-1 receptor agonist that is known to possess anti-diabetic effects and does not degrade for hours, making it a superior candidate for such disorders. Moreover, exendin-4's neuroprotective effects have been reported in several preclinical studies. Exendin-4's diverse therapeutic targets suggest its potential therapeutic uses in neurodegenerative ailments like Alzheimer's disease and Parkinson's disease and have garnered an increasing amount of attention. Given the substantial body of evidence supporting the neuroprotective potential of exendin-4 in various research models, this article is dedicated to exploring the promising role of exendin-4 as a therapeutic agent for the treatment and management of Alzheimer's disease and Parkinson's disease. This review draws insights from the findings of numerous preclinical and clinical studies to highlight the collective neuroprotective advantages of exendin-4 and the potential mechanisms that underlie its neuroprotective effects.


Subject(s)
Alzheimer Disease , Neurodegenerative Diseases , Neuroprotective Agents , Parkinson Disease , Humans , Exenatide/therapeutic use , Parkinson Disease/drug therapy , Glucagon-Like Peptide 1/agonists , Glucagon-Like Peptide 1/metabolism , Glucagon-Like Peptide 1/therapeutic use , Alzheimer Disease/drug therapy , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Neurodegenerative Diseases/drug therapy
4.
J Biochem Mol Toxicol ; 38(1): e23619, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38091364

ABSTRACT

Neurodegenerative disorders (NDs) are defined as the slow loss of a group of neurons that are particularly sensitive. Due to the intricate pathophysiological processes underlying neurodegeneration, no cure exists for these conditions despite the extensive research and advances in our knowledge of the onset and course of NDs. Hence, there is a medical need for the creation of a novel therapeutic approach for NDs. By focusing on numerous signaling pathways, some natural substances derived from medicinal herbs and foods have demonstrated potent activity in treating various NDs. In this context, flavonoids have recently attracted increased popularity and research attention because of their alleged beneficial effects on health. By acting as antioxidant substances, nutritional supplements made up of flavonoids have been found to lessen the extent of NDs like Alzheimer's disease (AD) and Parkinson's disease (PD). Luteolin is a flavone that possesses potent antioxidant and anti-inflammatory properties. As a consequence, luteolin has emerged as an option for treatment with therapeutic effects on many brain disorders. More research has focused on luteolin's diverse biological targets as well as diverse signaling pathways, implying its potential medicinal properties in several NDs. This review emphasizes the possible use of luteolin as a drug of choice for the treatment as well as the management of AD and PD. In addition, this review recommends that further research should be carried out on luteolin as a potential treatment for AD and PD alongside a focus on mechanisms and clinical studies.


Subject(s)
Alzheimer Disease , Parkinson Disease , Humans , Parkinson Disease/drug therapy , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Antioxidants/pharmacology , Antioxidants/therapeutic use , Luteolin/pharmacology , Luteolin/therapeutic use , Flavonoids/therapeutic use
5.
J Emerg Trauma Shock ; 7(3): 155-9, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25114423

ABSTRACT

CONTEXT: The scope of ultrasound is emerging in medical science, particularly outside traditional areas of radiology practice. AIMS: We designed this study to evaluate feasibility of bedside sonography as a tool for airway assessment and to describe sonographic anatomy of airway. SETTINGS AND DESIGN: A prospective, clinical study. MATERIALS AND METHODS: We included 100 adult, healthy volunteers of either sex to undergo airway imaging systemically starting from floor of the mouth to the sternal notch in anterior aspect of neck by sonography. RESULTS: We could visualize mandible and hyoid bone as a bright hyperechoic structure with hypoechoic acoustic shadow underneath. Epiglottis, thyroid cartilage, cricoid cartilage, and tracheal rings appeared hypoechoic. Vocal cords were visualized through thyroid cartilage. Interface between air and mucosa lining the airway produced a bright hyperechoic linear appearance. Artifacts created by intraluminal air prevented visualization of posterior pharynx, posterior commissure, and posterior wall of trachea. CONCLUSIONS: Ultrasound is safe, quick, noninvasive, repeatable, and bedside tool to assess the airway and can provide real-time dynamic images relevant for several aspects of airway management.

SELECTION OF CITATIONS
SEARCH DETAIL
...